Please login to the form below

Not currently logged in
Email:
Password:

Merck pays Vertex $230m upfront for cancer programmes

Licences four DNA damage and repair programmes with first-in-class or best-in-class potential
Merck KGaA

Merck KGaA has licensed four DNA damage and repair programmes from Vertex Pharma that it says will complement its push into cancer immunotherapy.

The German pharma company is paying $230m upfront for rights to two clinical-stage programmes and two more in preclinical development and says they all have "first-in-class and best-in-class potential".

Merck's chief executive Belen Garijo said combining DNA damage and repair with immuno-oncology agents such as its Pfizer-partnered checkpoint inhibitor avelumab has "promising therapeutic synergy". It is widely believed that combining immuno-oncology agents with other therapies will unlock additional efficacy gains.

The first clinical programme includes two candidates targeting an enzyme known as ataxia telangiectasia and Rad3 related (ATR) - also known as FRP1 - that is involved in sensing DNA damage and delaying cell cycling in order to allow time for repair. Inhibiting the enzyme can kill cancer cells directly as well as sensitise them to other anticancer drugs.

The two compounds, VX-970 and oral candidate VX-803, have reached phase II and phase I clinical development, respectively, in a variety of tumour types. Last year, Vertex reported phase I data on VX-970 showing that injections of the drug could achieve partial responses in patients with solid tumours that were resistant to platinum-based chemotherapy.

Meanwhile, Merck has also negotiated rights to a DNA-dependent protein kinase (DNA-PK) inhibitor programme headed by VX-984, which is in phase I testing. Like ATR, DNA-PK is a key component of the DNA repair machinery and Merck already has its own inhibitors in development.

The ongoing trial is testing VX-984 alone and with liposomal doxorubicin in patients with advanced solid tumours.

Merck is giving less information out on the preclinical programmes, but said they include "one immuno-oncology programme against an attractive target with first-in-class potential, and a programme against a completely novel target".

Merck is taking over full responsibility for the development and commercialization of all the in-licensed candidates.

For Vertex, the deal provides a cash injection while allowing it to concentrate on core projects such as cystic fibrosis and therapies for other rare diseases, according to analysts at Jefferies.

Article by
Phil Taylor

13th January 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Windrose Consulting Group

Founded in 2015, Windrose Consulting Group is a privately-held global strategy firm that partners with life science companies to maximize...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....